The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will join hands to organise the first ever European CAR T Cell Meeting. The meet will be held in Paris on 14–16 February 2019.
CAR T Cell Therapy is bringing a silent revolution in the field of hematologic malignancies. It has potential to achieve cure for many dreadful diseases. Its emergence will provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment.
Christian Chabannon, Chair, EBMT Cellular Therapy & Immunobiology Working Party and EBMT Scientific Council Vice-Chair, says: “The EBMT and EHA unite in designing this first-ever European Meeting which represents an amazing educational opportunity for healthcare professionals to get practical information to safely administer CAR-T Cells to a growing number of patients, both in Europeand worldwide.”
Hermann Einsele, Chair of the EHA Scientific Working Group on Immune Therapies for Hematologic Disorders adds: “Experts with various backgrounds and expertise will share their knowledge about CAR-T Cell Therapy and provide an overview of their current and future applications in cancer treatment, and how this translates in healthcare organizations.”
The meet will offer a comprehensive outlook on the current research efforts to increase the efficacy of CAR T Cell Therapy, with inputs from basic researchers as well as debates involving representatives from industry.
It is time new technologies in the medical field were discussed and analysed more in public domain.